Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Gabriel N. Hortobagyi, Henry L. Gomez, Rubi K. Li, Hyun Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Guillermo L. Lerzo, Xavier B. Pivot, Fernando Hurtado De Mendoza, Binghe Xu, Linda T. Vahdat, Ronald A. Peck, Pralay Mukhopadhyay, Henri H. Roché

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Limited proven treatment options exist for patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane treatment. Ixabepilone, a novel semisynthetic analog of epothilone B, has demonstrated single-agent activity in MBC resistant to anthracyclines and taxanes. In combination with capecitabine in a phase III trial (CA163-046) in this setting, ixabepilone prolonged progression-free survival and increased objective response rate relative to capecitabine (Thomas et al. J Clin Oncol 25:5210-5217, 2007). Here, we report the results of overall survival (OS), a secondary efficacy endpoint from the CA163-046 trial. Seven hundred fifty-two patients with MBC resistant to anthracyclines and taxanes were randomized to ixabepilone (40 mg/m2 intravenously on day 1 of a 21-day cycle) plus capecitabine (2,000 mg/m 2 orally on days 1 through 14 of a 21-day cycle) or capecitabine alone (2,500 mg/m2 on the same schedule). Patients receiving ixabepilone plus capecitabine treatment had a median survival of 12.9 months compared to 11.1 months for patients receiving capecitabine alone (HR = 0.9; 95%CI: 077-1.05; P = 0.19). This observed increase in median OS favored the combination; however, the difference was not statistically significant. Predefined subset analyses showed a clinically meaningful increase in OS in KPS 70-80 patients receiving ixabepilone plus capecitabine (HR = 0.75; 95% CI: 0.58-0.98). Ixabepilone plus capecitabine did not show a significant improvement in survival compared to capecitabine alone in patients with MBC resistant to anthracyclines and taxanes. The observed differences in survival favored the combination arm. A clinical benefit was also seen in patients in the KPS 70-80 subgroup (ClinicalTrials.gov number, NCT000080301).

Original languageEnglish
Pages (from-to)409-418
Number of pages10
JournalBreast Cancer Research and Treatment
Volume122
Issue number2
DOIs
Publication statusPublished - 2010 Jul

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes'. Together they form a unique fingerprint.

  • Cite this

    Hortobagyi, G. N., Gomez, H. L., Li, R. K., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., Lerzo, G. L., Pivot, X. B., De Mendoza, F. H., Xu, B., Vahdat, L. T., Peck, R. A., Mukhopadhyay, P., & Roché, H. H. (2010). Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment, 122(2), 409-418. https://doi.org/10.1007/s10549-010-0901-4